BURL Concepts Receives FDA Clearance for Groundbreaking Ultrasound System for PFO Screening

BURL Concepts, a San Diego-based medtech company, has recently achieved a significant milestone with the FDA granting 510(k) clearance for its innovative FOQUS™ ultrasound system. This advanced medical device is designed for the rapid, automated screening of patent foramen ovale (PFO), a common heart condition associated with cryptogenic strokes.

The FOQUS system stands out by utilizing SONAS technology, enabling it to conduct a comprehensive brain scan for emboli in just 40 seconds. This remarkable efficiency allows healthcare professionals to identify right-to-left shunts, such as PFOs, in a streamlined manner. The test can be executed by a single nurse in various healthcare settings, including physician offices, diagnostic centers, and hospitals, eliminating the need for a cardiologist to be present during the procedure.

PFOs are openings between the left and right atria of the heart that fail to close naturally after birth, and they are found in approximately 40 to 50 percent of patients who experience cryptogenic strokes. Detecting these conditions is vital for preventing additional strokes, making the introduction of the FOQUS system a critical advancement in stroke prevention strategies.

Unlike traditional transcranial Doppler (TCD) ultrasound methods, which require a skilled operator to pinpoint specific vessel segments, FOQUS operates autonomously. It employs low-energy, low-frequency ultrasound waves that can penetrate the skull effectively to assess the entire brain. This not only simplifies the testing process but also yields instant and objective data, providing physicians with a comprehensible results report that indicates whether embolic signals were detected.

Matthew J. Price, a prominent physician involved in the advancement of this technology, emphasized the significance of the FOQUS system in transforming the way PFOs are diagnosed. He stated, "Identifying a PFO in a patient who has had a cryptogenic stroke is a critical step toward preventing the next one. FOQUS provides a straightforward, objective evaluation without the complexity of traditional methods."

The system, although recently cleared by the FDA, has already seen early applications in the Netherlands and the UK, where initial trials have successfully detected embolic signals connected to right-to-left shunting in patients. BURL Concepts is now gearing up for the U.S. commercial launch of FOQUS in early 2027, focusing on both cardiology practices and outpatient diagnostic centers.

Peter van der Sluis, the CEO of BURL Concepts, expressed enthusiasm for this regulatory approval, referring to it as a defining moment for the company. He stated, "Our goal is to facilitate more efficient testing and enhance accessibility for patients. Much like how cardiac arrhythmia monitoring has advanced into outpatient environments, we envision FOQUS broadening access to crucial transcranial ultrasound testing."

With the FOQUS ultrasound system, patients will have access to a rapid and less invasive method of PFO screening. This technology has the potential to significantly shift the landscape of stroke prevention by providing quicker access to essential diagnostics, ultimately improving patient care and outcomes in a critical healthcare area.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.